IPO - CITIUS ONCOLOGY, INC.

Form Type: S-1

Filing Date: 2025-07-14

Corporate Action: Ipo

Type: New

Accession Number: 000121390025063483

Filing Summary: Citius Oncology, Inc. is filing its Registration Statement with the SEC to offer up to $15 million of shares of common stock and associated warrants targeting oncology therapies. The registration follows the FDA approval of its lead product, LYMPHIR, designed for treating a rare form of non-Hodgkin lymphoma. As the company transitions from Citius Pharmaceuticals, it indicates a focus on capital acquisition to support its commercial efforts. The document outlines obligations to Eisai under a licensing agreement and terms related to placement agent fees, alongside stringent risk factors reflecting operational and financial challenges.

Form Type: S-1/A

Filing Date: 2025-07-14

Corporate Action: Ipo

Type: New

Accession Number: 000121390025063793

Filing Summary: Citius Oncology, Inc. is filing this S-1/A registration statement for an initial public offering where it plans to offer up to 5,319,149 shares of common stock along with pre-funded warrants and accompanying warrants. This offering is designed to raise capital for the company, which specializes in developing targeted oncology therapies. The company has a leading product LYMPHIR, which was approved by the FDA in August 2024 for treating a specific form of non-Hodgkin lymphoma. The common stock is to be sold at an assumed price of $2.82, with provisions for various conditions surrounding warrant issuance and stockholder approval. The offering is expected to close within approximately two business days after commencement, set to terminate on July 29, 2025, unless ended sooner. The registration statement highlights risks associated with the proposed public offering, including a history of losses and dependence on the commercial success of LYMPHIR. Additionally, the company has undertaken a significant increase in authorized shares to support future growth. The offering will not only maximize the fundraising potential but is also crucial for Citius's operational financing needs moving forward. Regulatory compliance with Nasdaq listing rules is highlighted, alongside a recent assurance of compliance with NASDAQ's minimum bid price requirement. The placement agent for the offering is Maxim Group LLC, responsible for facilitating market offers to potential investors, with a detailed summary of agent fees outlined in the document.

Form Type: DRS

Filing Date: 2025-04-28

Corporate Action: Ipo

Type: New

Accession Number: 000121390025036067

Filing Summary: Citius Oncology, Inc. is filing a confidential draft submission under Section 106(a) of the Jumpstart Our Business Startups Act for a proposed public offering of its securities. The company is offering up to shares of common stock and warrants, including pre-funded warrants, to purchase its common stock. The public offering price will be determined at the time of pricing, with the offering being underwritten on a firm commitment basis. The company is an emerging growth company and smaller reporting company that has a primary focus on developing oncology therapies. The offering is aimed at raising capital to support product commercialization and development, specifically for their FDA-approved product LYMPHIR. Recent activities include a merger with TenX Keane Acquisition, transformation into Citius Oncology, Inc., and an increase in authorized shares. The offering also comes with associated underwriting risks and potential for limited liquidity due to the nature of the securities involved.